From “blockbusters” to “biosimilars”: An opportunity for patients, medical specialists and health care providers

Advances in basic research and research and development plans of pharmaceutical companies are radically changing the kind of available drugs and therapeutic targets. We are switching from predominantly chemical molecules, aimed at treating large populations of patients (blockbuster drugs), to a new...

Full description

Saved in:

Bibliographic Details
Published in:	Pulmonary pharmacology & therapeutics Vol. 25; no. 6; pp. 483 - 486
Main Authors:	Braido, F., Holgate, S., Canonica, G.W.
Format:	Journal Article
Language:	English
Published:	England Elsevier Ltd 01.12.2012
Subjects:	Asthma Biological Products - administration & dosage Biological Products - adverse effects Biological Products - therapeutic use Biosimilar Pharmaceuticals - administration & dosage Biosimilar Pharmaceuticals - adverse effects Biosimilar Pharmaceuticals - therapeutic use Biosimilars Biotech Drug Design Drug Industry - methods Drug Monitoring - methods Drugs, Generic - administration & dosage Drugs, Generic - therapeutic use Humans Medical Education Molecular Targeted Therapy Patents as Topic Precision Medicine - methods Pulmonary/Respiratory Biotech Biosimilars Asthma
ISSN:	1094-5539, 1522-9629, 1522-9629
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!